Proparacaine hydrochloride
PreclinicalSmall molecule
Proparacaine hydrochloride is one of 77 small molecule programs targeting Cataract. It is currently in Preclinical.
2
Indications
3
Total Trials
0
Active Trials
76
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
63 competitors in Cataract
#DrugCompanyPhaseTrials
1Avelox
BayerApproved
Eylea
RegeneronApproved
Decadron
AAspen Global Incorporated
Approved
Bromday
BBausch Health Americas, Inc.
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Lovenox
SanofiApproved
Voltaren
NovartisApproved
Cipro
BayerApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Levaquin
WWim Janssens
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
AIN1 trial
Proparacaine and Mydriatic Eye Drops
Terminated·—·N/A·NCT01266824·5 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Proparacaine hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SSun Yat-sen University